EGLN3 and renal carcinoma: Apart from its interaction with HIF1α, PHD3 has also been suggested to hydroxylate other targets, e.g., those involved in the glucose metabolism pathway, regulating their availability, as shown in other models, e.g., human renal carcinoma cells and mice hepatocytes [52,53].